News

For 2008, Emergent reported net income of $20.7 million, or $0.68 diluted earnings per share, compared to $22.9 million, or $0.77 diluted earnings per share for 2007. The

For full year 2008, the company reported net loss of $18.5 million, or $0.36 basic and diluted net loss per share, a 58% reduction compared to a net

For full year 2008, the company reported net loss applicable to common stock shareholders of $15.84 million, or $0.32 diluted net loss per common share, compared to a

For full year 2008, net loss was $41.6 million, or $0.64 basic and diluted net loss per share, compared to net loss of $42.2 million, or $0.96 basic

Novavax, a biopharmaceutical company, has announced encouraging results from a preclinical study of a respiratory syncytial virus vaccine candidate directed against the viral fusion protein. The virus utilizes

Nektar Therapeutics, a biopharmaceutical company, has reported positive topline results from a Phase II double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation. The Phase II

Net income for the year ended December 31, 2008 was $3.63 million, or $0.32 per diluted share, compared with $6.04 million, or $0.53 per diluted share in 2007.

GPC Biotech, a publicly traded biopharmaceutical company, has reported encouraging data from the double-blind, randomized satraplatin Phase III trial, the Sparc trial. The Sparc trial evaluated satraplatin plus

Amicus Therapeutics, a biopharmaceutical company, has suspended enrollment for the Phase II clinical trial of its investigational drug AT2220 for the treatment of Pompe disease and that it